Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

Zynerba Pharmaceuticals Valuation

Is ZYNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZYNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZYNE ($1.3) is trading below our estimate of fair value ($53.8)

Significantly Below Fair Value: ZYNE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZYNE?

Key metric: As ZYNE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ZYNE. This is calculated by dividing ZYNE's market cap by their current book value.
What is ZYNE's PB Ratio?
PB Ratio2.3x
BookUS$29.02m
Market CapUS$65.60m

Price to Book Ratio vs Peers

How does ZYNE's PB Ratio compare to its peers?

The above table shows the PB ratio for ZYNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.4x
LABP Landos Biopharma
3.1x-37.1%US$71.7m
MRMD MariMed
0.8xn/aUS$57.2m
RGC Regencell Bioscience Holdings
9.5xn/aUS$77.9m
NTRB Nutriband
4.3xn/aUS$53.8m
ZYNE Zynerba Pharmaceuticals
2.3x67.2%US$65.6m

Price-To-Book vs Peers: ZYNE is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (16.4x).

Price to Book Ratio vs Industry

How does ZYNE's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.09xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.20m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.71m
CLVR Clever Leaves Holdings
0.07xn/aUS$1.75m
ZYNE 2.3xIndustry Avg. 1.8xNo. of Companies31PB01.22.43.64.86+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ZYNE is expensive based on its Price-To-Book Ratio (2.3x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is ZYNE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZYNE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZYNE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZYNE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Sep ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Aug ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jul ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jun ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
May ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Apr ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Mar ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Feb ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jan ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Dec ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’24US$1.28
US$1.26
-1.6%
11.6%US$1.40US$1.11n/a2
Sep ’24US$1.32
US$1.26
-4.9%
11.6%US$1.40US$1.11n/a2
Aug ’24US$0.35
US$5.80
+1,533.8%
69.1%US$10.00US$0.40n/a3
Jul ’24US$0.33
US$5.80
+1,679.1%
69.1%US$10.00US$0.40n/a3
Jun ’24US$0.32
US$5.10
+1,479.9%
72.1%US$10.00US$0.40n/a4
May ’24US$0.36
US$5.38
+1,384.8%
74.2%US$11.00US$0.50n/a4
Apr ’24US$0.43
US$5.38
+1,150.0%
74.2%US$11.00US$0.50n/a4
Mar ’24US$0.46
US$5.44
+1,075.2%
71.9%US$11.00US$0.76n/a4
Feb ’24US$0.64
US$5.44
+751.3%
71.9%US$11.00US$0.76n/a4
Jan ’24US$0.53
US$5.44
+926.4%
71.9%US$11.00US$0.76n/a4
Dec ’23US$0.56
US$6.44
+1,050.0%
57.9%US$11.00US$0.76n/a4
Nov ’23US$0.73
US$6.50
+791.0%
56.0%US$11.00US$1.00n/a4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

7D

8.2%

1Y

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.5%

1Y

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

-0.2%

1Y

-7.1%